Samson Clinical Operations Pty Ltd

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Activity

Key Events

Mar 30, 2026FDAAdrenaline — EPINEPHRINE

Jul 14, 2025TrialEfficacy & Safety of Minoxidil SL Tablets in Men With AGA

Mar 13, 2025FDAAdrenaline — EPINEPHRINE

Mar 5, 2025FDAAdrenaline — NEFFY

Feb 3, 2025FDAKynmobi — ONAPGO

Nov 6, 2024TrialPhase 1 Pharmacokinetic Study of Minoxidil SL Tablets

Mar 4, 2024FDAAdrenaline — EPINEPHRINE

Apr 21, 2023FDAAdrenaline — ADRENALIN

2 more events

Aug 15, 2022FDAAdrenaline — EPINEPHRINE

May 21, 2020FDAKynmobi — KYNMOBI

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

15 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Adrenaline2 patentsJan 26, 2026 XadagoJun 8, 2027 AdrenalineNov 25, 2028 XadagoDec 10, 2028 KynmobiAug 7, 2029 Kynmobi6 patentsJun 11, 2030 XadagoMar 21, 2031 Kynmobi3 patentsDec 16, 2031

7 more

Adrenaline4 patentsMar 13, 2035 Kynmobi2 patentsApr 19, 2036 AdrenalineOct 20, 2036 Adrenaline3 patentsDec 21, 2037 Adrenaline2 patentsFeb 6, 2038 Adrenaline10 patentsFeb 6, 2039 AdrenalineJan 17, 2045

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Adrenaline — BRONKAID MIST

Application NDA016803 (NDA)

19951 event

FDAAug 3

Adrenaline — EPI E Z PEN JR

Application NDA019430 (NDA)

19991 event

FDAFeb 5

Adrenaline — SUS-PHRINE SULFITE FREE

Application NDA007942 (NDA)

20041 event

FDAApr 20

Kynmobi — APOKYN

Application NDA021264 (NDA)

20091 event

FDANov 25

Adrenaline — ADRENACLICK

Application NDA020800 (NDA)

20121 event

FDADec 7

Adrenaline — ADRENALIN

Application NDA204200 (NDA)

20131 event

FDADec 18

Adrenaline — ADRENALIN

Application NDA204640 (NDA)

20172 events

FDANov 17

Adrenaline — AUVI-Q

Application NDA201739 (NDA)

FDAMar 21

Xadago — XADAGO

Application NDA207145 (NDA)

20182 events

FDANov 7

Adrenaline — PRIMATENE MIST

Application NDA205920 (NDA)

FDASep 27

Adrenaline — SYMJEPI

Application NDA207534 (NDA)

20191 event

FDANov 5

Adrenaline — EPINEPHRINE

Application NDA209359 (NDA)

20201 event

FDAMay 21

Kynmobi — KYNMOBI

Application NDA210875 (NDA)

20221 event

FDAAug 15

Adrenaline — EPINEPHRINE

Application NDA211363 (NDA)

20231 event

FDAApr 21

Adrenaline — ADRENALIN

Application NDA215875 (NDA)

20241 event

FDAMar 4

Adrenaline — EPINEPHRINE

Application NDA205029 (NDA)

20253 events

FDAMar 13

Adrenaline — EPINEPHRINE

Application NDA215425 (NDA)

FDAMar 5

Adrenaline — NEFFY

Application NDA214697 (NDA)

FDAFeb 3

Kynmobi — ONAPGO

Application NDA214056 (NDA)

20261 event

FDAMar 30

Adrenaline — EPINEPHRINE

Application NDA220626 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)